We are Sorry, This Page doesn't Exist

Eli Lilly's treatment reduced a harmful substance in the brains of patients with Alzheimer's disease and slowed their rate of cognitive decline. Patients sit inside the Alzheimer's Foundation in Mexico City Thomson Reuters Eli Lilly's.....»»

Shares of Cassava Sciences Inc. more than doubled toward a near 10-year high in very active trading Tuesday, after the company focused on neurodegenerative disease treatments announced upbeat results from a stu.....»»

Shares of Biogen Inc. gained 5.6% in trading on Monday after another drugmaker shared positive clinical data about an experimental Alzheimer's disease treatment that is similar to a Biogen therapy under review by the Food and Drug A.....»»

Shares of Cassava Sciences Inc. tumbled 73.2% in trading on Friday after the company said its investigational Alzheimer's disease treatment failed a mid-.....»»

As the novel coronavirus spreads across the globe and scientists race to develop treatments for the disease, experts at Duke Clinical Research Institute say there are ways to improve trials for a potential treatment currently underway in China......»»

Neurotrope released a corporate update after analyzing data from its recently reported Phase 2 confirmatory clinical trial examining moderately severe to severe Alzheimer's disease patients......»»

“This asset is highly complementary to our existing pipeline of potential disease-modifying therapies in Alzheimer’s and Parkinson’s diseases,” Biogen Chief Medical Officer Alfred Sandrock Jr. said in a statement......»»

Biogen Inc. said Monday it will buy from Pfizer Inc. a potential treatment for behavioral and neurological symptoms, as a potential treatment for Alzheimer's and Parkinson's, for an upfront payment of $75 million and up to $635 million in pote.....»»

‘Interest in treatment and prevention have shifted earlier in the disease process.’.....»»

A Triangle company looking to stop Alzheimer’s Disease has closed a sizable fundraising round to push forward its pipeline......»»

An experimental treatment for Alzheimer's disease declared a failure in March has been brought back to life......»»

Shares of Biogen Inc. fell 1.6% in premarket trading Friday, after the the biotechnology company and Tokyo-based Eisai Co. Ltd. said they will discontinue the phase 3 trial of an Alzheimer's disease.....»»

Analyst Yun Zhong looks at two treatments for Alzheimer Disease and other dementias that could beat the odds and be winners in treating these awful afflictions......»»

The Maryland biotechnology company founded by a former satellite broadcasting executive to develop a treatment for her daughter’s rare disease is the target of a lawsuit......»»

Biogen and partner Eisai Co Ltd are ending two late-stage trials testing the experimental Alzheimer's drug aducanumab, marking the latest setback for an industry racing to develop treatments for the memory-robbing disease......»»

The two IPOs on this week's calendar include one tech unicorn and a biotech working on a treatment from Alzheimer disease......»»

This finding could pave the wave for Alzheimer's treatment and biomarkers for early diagnosis......»»

A newly launched biotech company has secured $65 million in financing as it seeks to develop the first-ever treatment for a disorder that its co-founder described as “the life being squeezed out of the liver.” Cambridge-based Akero Therapeutics is fo.....»»

The experimental treatment slowed the disease, but not enough to meet investors' high expectations.....»»

Incon Co., a publicly traded South Korean biotech investor, has given Weston-based Variant Pharmaceuticals $10 million in financing in exchange for equity ownership. The funding will be used to develop VAR 200 for the treatment of rare kidney disease .....»»